Research and Markets: U.S. Colony Stimulating Factors Market: Provides Scenarios of How the Market Might Evolve in 2014

28-10-2013 Business Wire HealthComments (0)

PharmaceuticalTeva Pharmaceutical Industries

Research and Markets ( has announced the addition of the "U.S. Colony Stimulating Factors Market" report to their offering. In August 2012, the FDA approved Teva's tbo-filgrastim. The approval was based on a full Biologic License Application (BLA) rather than under the FDA's new biosimilar approval pathway. Due to a court ruling related to Amgen's filgrastim patents, Teva will be able to start selling its prod

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top